drugset / Trial / NCT00429091

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00429091

Phase 2 Completed 243 enrolled Abbott
RandomizedCrossoverQuadruple-blindTreatment

Summary

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Timeline

Start
2007-01
Primary completion
2007-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atomoxetine Other / unclassified 40 mg
Subject SOFINICLINE Small molecule 1 mg
Subject SOFINICLINE Small molecule 2 mg
Subject SOFINICLINE Small molecule 4 mg